Dr. Hofmeister on Reolysin Combined With Carfilzomib for Multiple Myeloma

Craig Hofmeister, MD, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University, discusses a study that examined the efficacy of reolysin combined with carfilzomib in patients with relapsed multiple myeloma.

This phase I dose-escalation study examined the relapsed population, as well as some patients who were refractory to carfilzomib, Hofmeister explains. A total of 12 patients received the combination of reolysin, an oncolytic virus, and carfilzomib at two different levels.

At the starting dose level, all patients responded to the regimen; 6 patients were able to remain on therapy without disease progression. At a decreased dose, the majority of patients did not respond to the combination, which was an unexpected result, Hofmeister says.